<DOC>
	<DOCNO>NCT02799862</DOCNO>
	<brief_summary>This single-arm non-interventional study ( NIS ) evaluate effectiveness , safety quality life ( QoL ) patient advance NSCLC receive combination nab-paclitaxel carboplatin first line palliative therapy real life setting .</brief_summary>
	<brief_title>Nab-Paclitaxel Combination With Carboplatin First-line Therapy Patients With NSCLC</brief_title>
	<detailed_description>The present NIS design provide additional knowledge term effectiveness , safety quality life routine administration combination nab-paclitaxel ( Abraxane® ) carboplatin first line treatment adult patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) candidate potentially curative surgery / radiation therapy . The combination Abraxane® carboplatin approve Europe March 2015 base result pivotal randomize , open label phase III study 1,052 patient .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm diagnosis locally advance / metastatic , unresectable NSCLC According SmPC According SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>unresectable</keyword>
	<keyword>NSCLC</keyword>
</DOC>